8-K
filed July 14, 2023, 7:59 PM ET
ticker CVKD
CIK 0001937993
other material
confidence high
sentiment neutral
materiality 0.60
Cadrenal Therapeutics closes $7.5 million private placement of common stock and warrants
Cadrenal Therapeutics, Inc.
- Closed offering of 4,285,715 shares (or pre-funded warrants) at $1.75 per share, raising ~$7.5M gross.
- Issued warrants to purchase 4,285,715 shares at $1.75, exercisable for 5.5 years from issuance.
- Net proceeds to be used for working capital to advance tecarfarin development.
- Directors and officers subject to 60-day lock-up after registration statement effectiveness.
- Placement agent H.C. Wainwright; Boustead Securities acted as financial advisor.
Key facts
Extracted from this filing and checked against the source text.
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.9
Cadrenal Therapeutics, Inc. entered into Engagement Agreement with H.C. Wainwright & Co., LLC (effective 2023-07-12).
- Action
- entry
- Agreement
- underwriting
- Counterparty
- H.C. Wainwright & Co., LLC
- Effective
- 2023-07-12
Exact text from the filing
Pursuant to a letter agreement dated July 12, 2023 (the “Engagement Agreement”), H.C. Wainwright & Co., LLC (“HWC”) acted as placement agent for the Private Placement.
View on SEC.gov
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.9
Cadrenal Therapeutics, Inc. entered into Registration Rights Agreement with the Investor (effective 2023-07-12).
- Action
- entry
- Agreement
- equity purchase
- Counterparty
- the Investor
- Effective
- 2023-07-12
Exact text from the filing
In connection with the Private Placement, the Company has entered into a registration rights agreement (the “Registration Rights Agreement”) with the Investor, dated July 12, 2023
View on SEC.gov
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.9
Cadrenal Therapeutics, Inc. entered into Purchase Agreement with an institutional accredited investor valued at approximately $7.5 million (effective 2023-07-12).
- Action
- entry
- Agreement
- equity purchase
- Counterparty
- an institutional accredited investor
- Value
- approximately $7.5 million
- Effective
- 2023-07-12
Exact text from the filing
On July 12, 2023, Cadrenal Therapeutics, Inc. (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with an institutional accredited investor (the “Investor”)
View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.